Clinical Trials Browser

Phase 2 × Completed × ublituximab × Clear all

NCT04508647 2024-03-21

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Phase 2 Completed

4 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone